Discovery of clinical candidate methyl (5-(6-((4(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) : A highly potent and selective PI3K alpha inhibitor for the treatment of advanced solid tumors

doi:10.1158/1538-7445.AM2018-LB-268

	Discovery of clinical candidate methyl (5-(6-((4(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) : A highly potent and selective PI3K alpha inhibitor for the treatment of advanced solid tumors
	Xiang, Haoyue; Wang, Xiang; Chen, Yanhong; Zhang, Xi; Chen, Yi; Tan, Cun; Wang, Yi; Ding, Jian; Meng, Ling-Hua; Yang, Chunhao
刊名	CANCER RESEARCH
	2018-07-01
卷号	78 期号:13 页码:2
ISSN号	0008-5472
DOI	10.1158/1538-7445.AM2018-LB-268
WOS研究方向	Oncology
语种	英语
出版者	AMER ASSOC CANCER RESEARCH
WOS记录号	WOS:000468818900414
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/289602]
专题	中国科学院上海药物研究所
作者单位	Shanghai Inst Mat Med, Shanghai, Peoples R China
推荐引用方式 GB/T 7714	Xiang, Haoyue,Wang, Xiang,Chen, Yanhong,et al. Discovery of clinical candidate methyl (5-(6-((4(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) : A highly potent and selective PI3K alpha inhibitor for the treatment of advanced solid tumors[J]. CANCER RESEARCH,2018,78(13):2.
APA	Xiang, Haoyue.,Wang, Xiang.,Chen, Yanhong.,Zhang, Xi.,Chen, Yi.,...&Yang, Chunhao.(2018).Discovery of clinical candidate methyl (5-(6-((4(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) : A highly potent and selective PI3K alpha inhibitor for the treatment of advanced solid tumors.CANCER RESEARCH,78(13),2.
MLA	Xiang, Haoyue,et al."Discovery of clinical candidate methyl (5-(6-((4(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) : A highly potent and selective PI3K alpha inhibitor for the treatment of advanced solid tumors".CANCER RESEARCH 78.13(2018):2.